

Paper No. _____
Filed: November 23, 2015

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

INNOPHARMA LICENSING, INC., INNOPHARMA LICENSING LLC,
INNOPHARMA INC., INNOPHARMA LLC,
MYLAN PHARMACEUTICALS INC., and MYLAN INC.,
Petitioners
v.

SENJU PHARMACEUTICAL CO., LTD.,
Patent Owner

Case IPR2016-00090
U.S. Patent 8,871,813

PATENT OWNER'S MANDATORY NOTICES
PURSUANT TO 37 C.F.R. § 42.8

Pursuant to 37 C.F.R. § 42.8(a)(2), Patent Owner Senju Pharmaceutical Co., Ltd. (“Senju”) hereby submits the following mandatory notices in connection with this proceeding.

I. SENJU’S POWER OF ATTORNEY

A Power of Attorney appointing lead and back-up counsel is being filed concurrently with these Notices.

II. SENJU’S MANDATORY NOTICES

(a) 37 C.F.R. § 42.8(b)(1): Real Party-in-Interest

The real party-in-interest for the Patent Owner is Senju Pharmaceutical Co., Ltd. Other real parties-in-interest include Bausch & Lomb Inc., and Bausch & Lomb Pharma Holdings Corp.

(b) Related Matters

1. Judicial

The patent challenged here, U.S. Patent 8,871,813 (“the ’813 patent”), has been asserted in the following litigations:

Case Caption	Case Number	Court	Filing Date
<i>Senju Pharm. Co., Ltd., Bausch & Lomb, Inc. and Bausch & Lomb Pharma Holdings Corp. v. Innopharma Licensing, Inc., Innopharma Licensing, LLC, Innopharma, Inc., and Innopharma LLC</i>	1:14-cv-06893	D.N.J.	Nov. 3, 2014
<i>Senju Pharm. Co., Ltd., Bausch & Lomb Inc. and Bausch & Lomb Pharma Holdings Corp. v. Lupin, Ltd. and Lupin Pharms., Inc.</i>	1:15-cv-00335	D.N.J.	Jan. 16, 2015

<i>Senju Pharm. Co. Ltd., Bausch & Lomb Inc. and Bausch & Lomb Pharma Holdings Corp. v. Apotex Inc. and Apotex Corp.</i>	1:15-cv-00336	D.N.J.	Jan. 16, 2015
<i>Senju Pharm. Co. Ltd., Bausch & Lomb Inc. and Bausch & Lomb Pharma Holdings Corp. v. Paddock Labs., LLC, L. Perrigo Co., and Perrigo Co.</i>	1:15-cv-00337	D.N.J.	Jan. 16, 2015
<i>Senju Pharm. Co. Ltd., Bausch & Lomb Inc. and Bausch & Lomb Pharma Holdings Corp. v. Paddock Labs., LLC, L. Perrigo Co., and Perrigo Co.</i>	1:15-cv-00087	D.Del.	Jan. 26, 2015
<i>Senju Pharm. Co. Ltd., Bausch & Lomb Inc. and Bausch & Lomb Pharma Holdings Corp. v. InnoPharma Licensing, Inc., Innopharma Licensing, LLC, Innopharma, Inc., Innopharma, LLC, Mylan Pharms., Inc., and Mylan Inc.</i>	1:15-cv-03240	D.N.J.	May 8, 2015
<i>Senju Pharm. Co. Ltd., Bausch & Lomb Inc. and Bausch & Lomb Pharma Holdings Corp. v. Watson Labs., Inc., Actavis, Inc. and Actavis Pharma, Inc.</i>	1:15-cv-05591	D.N.J.	Jul. 16, 2015

There are four other related patents currently involved in parallel district court proceedings, U.S. Patents Nos. 8,129,431 (“the ’431 patent”) 8,669,290 (“the ’290 patent”), 8,754,131 (“the ’131 patent”), and 8,927,606 (“the ’606 patent”). As the Patent Owner reads 37 C.F.R. § 42.8, Patent Owner is not required to individually identify these proceedings, but if the Board prefers them identified, Patent Owner will do so.

2. Administrative

Petitioner filed concurrently with this petition two other petitions for *inter partes* review: (1) IPR2016-00089 of the ’131 patent, and (2) IPR2016-00091 of the ’606 patent. Patent Owner identifies additional administrative matters related to this patent family:

Case Caption	IPR No.	Patent	Filed
<i>Metrics, Inc. v. Mayne Pharma, and Johnson Matthey, Inc. v. Senju Pharm. Co., Ltd, Bausch & Lomb, Inc., and Bausch & Lomb Pharma Holdings Corp.</i>	IPR2014-01041	8,129,431	June 26, 2014
<i>Metrics, Inc. v. Mayne Pharma, and Johnson Matthey, Inc. v. Senju Pharm. Co., Ltd, Bausch & Lomb, Inc., and Bausch & Lomb Pharma Holdings Corp.</i>	IPR2014-01043	8,669,290	June 26, 2014
<i>Innopharma Licensing, Inc., Innopharma Licensing, LLC, Innopharma, Inc., Innopharma LLC, Mylan Pharm. Inc., and Mylan Inc. v. Senju Pharm. Co., Ltd, Bausch & Lomb, Inc., and Bausch & Lomb Pharma Holdings Corp.</i>	IPR2015-00903	8,129,431	Mar. 19, 2015
<i>Innopharma Licensing, Inc., Innopharma Licensing, LLC, Innopharma, Inc., Innopharma LLC, Mylan Pharm. Inc., and Mylan Inc. v. Senju Pharm. Co., Ltd, Bausch & Lomb, Inc., and Bausch & Lomb Pharma Holdings Corp.</i>	IPR2015-00902	8,669,290	Mar. 19, 2015
<i>Lupin Ltd. and Lupin Pharm. Inc. v. Senju Pharm. Co., Ltd,</i>	IPR2015-01099	8,669,290	April 23, 2015
<i>Lupin Ltd. and Lupin Pharm. Inc. v. Senju Pharm. Co., Ltd,</i>	IPR2015-01097	8,754,131	April 23, 2015
<i>Lupin Ltd. and Lupin Pharm. Inc. v. Senju Pharm. Co., Ltd,</i>	IPR2015-01105	8,871,813	April 23, 2015
<i>Lupin Ltd. and Lupin Pharm. Inc. v. Senju Pharm. Co., Ltd,</i>	IPR2015-01100	8,927,606	April 23, 2015
<i>Lupin Ltd. and Lupin Pharm. Inc. v. Senju Pharm. Co., Ltd, Bausch & Lomb, Inc., and Bausch & Lomb Pharma Holdings Corp.</i>	IPR2015-01871	8,129,431	Sept. 9, 2015

**(b) 37 C.F.R. § 42.8(b)(3) and (4): Lead and Back-Up Counsel, and
Service Information**

Senju designates the following counsel to transact all business in the United States Patent & Trademark Office associated with the above-captioned proceeding.

Lead Counsel	Back-Up Counsel
Bryan C. Diner (Reg. No. 32,409) Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Avenue, NW Washington, DC 20001-4413 Phone: (202) 408-4116 Fax: (202) 408-4400 Email: Bryan.Diner@finnegan.com	Justin J. Hasford (Reg. No. 62,180) Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Avenue, NW Washington, DC 20001-4413 Phone: (202) 408-4175 Fax: (202) 408-4400 Email: Justin.Hasford@finnegan.com Joshua L. Goldberg (Reg. No. 59,369) Finnegan, Henderson, Farabow, Garrett & Dunner, LLP 901 New York Avenue, NW Washington, DC 20001-4413 Phone: (202) 408-6092 Fax: (202) 408-4400 Email: Joshua.Goldberg@finnegan.com

Please address all correspondence regarding this proceeding to lead and back-up counsel. Senju also consents to electronic service by email.

Respectfully submitted,

Dated: November 23, 2015

By: /Bryan C. Diner/
Bryan C. Diner, Lead Counsel
Reg. No. 32,409

Counsel for Patent Owner

CERTIFICATE OF SERVICE

The undersigned hereby certifies that a copy of the foregoing **Patent Owner's Mandatory Notices** was served on November 23, 2015, via email directed to counsel of record for the Petitioner at the following:

Jitendra Malik
jitty.malik@alston.com

Hidetada James Abe
james.abe@alston.com

Lance Soderstrom
lance.soderstrom@alston.com

Date: November 23, 2015

/Bradley J. Moore/
Bradley J. Moore
Litigation Clerk

Finnegan, Henderson, Farabow, Garrett &
Dunner, LLP